CPHI China 2026: The Definitive Hub for Global Pharma Supply Chain & Innovation
Date: June 16–18, 2026
Venue: Shanghai New International Expo Centre (SNIEC)
Scale: 240,000 sqm exhibition space, 3,600+ global exhibitors, 110,000+ professional visitors from 147+ countries
Co-located Events: PMEC China (pharmaceutical machinery), Biotech Zone, and 100+ industry conferences
1. Event Overview: Asia's Largest Pharma Industry Gathering
CPHI China (World Pharmaceutical Ingredients China) 2026 marks the 24th edition of Asia's most influential pharmaceutical sourcing and innovation platform. Hosted in Shanghai-the epicenter of China's pharma manufacturing and biotech innovation-the event covers the entire pharmaceutical value chain, from raw materials and APIs to finished formulations, biotech solutions, packaging, and machinery.
This year's show will feature 12 specialized zones, including API & Intermediates, Excipients, Biotech, Contract Services (CDMO/CMO), and Sustainable Manufacturing. The concurrent conference program will address critical industry topics: ICH-GMP compliance, regulatory harmonization, green chemistry, and the shift from generics to biologic innovation. With 26% of visitors coming from overseas, CPHI China 2026 serves as a critical bridge between Chinese manufacturers and global buyers.
2. Key Manufacturer Analysis
2.1 Domestic Leaders: Vertical Integration & Regulatory Compliance
Chinese pharmaceutical manufacturers dominate the API and intermediate segments, leveraging vertical integration and cost advantages while rapidly aligning with global quality standards.
API & Intermediate Champions: Hisun Pharmaceutical, Huahai Pharmaceutical, and Zhejiang Medicine lead in FDA/CEP-compliant generic APIs and complex intermediates. Their fully integrated operations (from raw materials to finished APIs) ensure cost efficiency and supply chain stability, making them preferred partners for global generic drugmakers.
Biotech Rising Stars: WuXi AppTec, BeiGene, and Innovent Biologics showcase cutting-edge cell/gene therapies, monoclonal antibodies, and bispecific drugs. These companies are driving China's transition from a generic manufacturing base to a global biotech innovation hub.
Specialty & Excipient Leaders: Companies like Qilu Pharmaceutical and CSPC Pharmaceutical excel in high-value specialty APIs and injectable formulations, while others focus on ICH Q7-compliant excipients for global markets.
2.2 International Players: High-Value Innovation & Niche Expertise
Global exhibitors at CPHI China 2026 focus on high-value products, advanced technologies, and regulatory expertise, targeting China's growing demand for premium pharma solutions.
Global Pharma Giants: EUROAPI (France), Merck (Germany), and Dr. Reddy's (India) showcase specialty APIs, complex intermediates, and bioprocessing technologies. They aim to partner with Chinese CDMOs and biotechs to expand their Asia-Pacific footprint.
European & Japanese Niche Suppliers: Firms like Lipoid GmbH (Germany) and Olon SPA (Italy) specialize in green chemistry, sustainable manufacturing, and high-purity excipients. Their expertise in eco-friendly production aligns with China's push for low-carbon pharma operations.
Packaging & Machinery Leaders: Companies such as Stevanato Group (Italy) and Datwyler (Switzerland) display aseptic packaging, drug delivery systems, and smart manufacturing equipment. These technologies support Chinese manufacturers in upgrading production lines for global compliance.
2.3 Emerging Trends Shaping the 2026 Show
Regulatory Alignment: A record number of Chinese exhibitors will highlight ICH-GMP, FDA, and CEP certifications, reflecting the industry's focus on global market access.
Biotech Expansion: The Biotech Zone (Halls W4 & W9) will see a 30% increase in exhibitors, with a focus on mRNA, cell therapy, and biomanufacturing solutions.
Sustainability as a Core Offering: Over 40% of exhibitors will showcase low-carbon production, circular economy, and waste-reduction technologies.
CDMO/CMO Growth: The Contract Services Zone will expand by 25%, driven by demand for end-to-end drug development and manufacturing solutions.
3. Why Attend CPHI China 2026
Source Compliant & Cost-Effective Products: Connect with 3,600+ vetted manufacturers offering FDA/CEP-compliant APIs, intermediates, and biotech solutions.
Forge Global Partnerships: Meet decision-makers from 147+ countries, including 26% overseas buyers, to build long-term supply chain collaborations.
Access Cutting-Edge Innovation: Explore the latest in biotech, green chemistry, and smart manufacturing across 12 specialized zones.
Stay Ahead of Industry Trends: Gain insights from 100+ conferences on regulatory updates, market shifts, and sustainability best practices.
4. Connect With Us at Booth W3A02
Our team will be at Booth W3A02 throughout the show, ready to discuss your sourcing needs, regulatory challenges, and innovation goals. Whether you're seeking vertically integrated API solutions, custom synthesis, or biotech partnerships, we look forward to connecting with you in Shanghai.